134 related articles for article (PubMed ID: 1551909)
21. C1 inhibitor: different mechanisms of reaction with complement component C1 and C1s.
Hortin GL; Trimpe BL
Immunol Invest; 1991 Feb; 20(1):75-82. PubMed ID: 2055603
[TBL] [Abstract][Full Text] [Related]
22. Interaction of C1-inhibitor with the C1r and C1s subcomponents in human C1.
Arlaud GJ; Reboul A; Sim RB; Colomb MG
Biochim Biophys Acta; 1979 Jan; 576(1):151-62. PubMed ID: 760802
[TBL] [Abstract][Full Text] [Related]
23. Interaction of human plasma kallikrein and its light chain with C1 inhibitor.
van der Graaf F; Koedam JA; Griffin JH; Bouma BN
Biochemistry; 1983 Sep; 22(20):4860-6. PubMed ID: 6556071
[TBL] [Abstract][Full Text] [Related]
24. A secondary C1s interaction site on C1-inhibitor is essential for formation of a stable enzyme-inhibitor complex.
He S; Sim RB; Whaley K
FEBS Lett; 1997 Mar; 405(1):42-6. PubMed ID: 9094421
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of action of anti-C1-inhibitor autoantibodies: prevention of the formation of stable C1s-C1-inh complexes.
He S; Sim RB; Whaley K
Mol Med; 1998 Feb; 4(2):119-28. PubMed ID: 9508789
[TBL] [Abstract][Full Text] [Related]
26. Serpins and the complement system.
Beinrohr L; Murray-Rust TA; Dyksterhuis L; Závodszky P; Gál P; Pike RN; Wijeyewickrema LC
Methods Enzymol; 2011; 499():55-75. PubMed ID: 21683249
[TBL] [Abstract][Full Text] [Related]
27. Crucial residues in the carboxy-terminal end of C1 inhibitor revealed by pathogenic mutants impaired in secretion or function.
Verpy E; Couture-Tosi E; Eldering E; Lopez-Trascasa M; Späth P; Meo T; Tosi M
J Clin Invest; 1995 Jan; 95(1):350-9. PubMed ID: 7814636
[TBL] [Abstract][Full Text] [Related]
28. X-ray structure of the Ca2+-binding interaction domain of C1s. Insights into the assembly of the C1 complex of complement.
Gregory LA; Thielens NM; Arlaud GJ; Fontecilla-Camps JC; Gaboriaud C
J Biol Chem; 2003 Aug; 278(34):32157-64. PubMed ID: 12788922
[TBL] [Abstract][Full Text] [Related]
29. Antibody-independent C1 activation by E. coli.
Tenner AJ; Ziccardi RJ; Cooper NR
J Immunol; 1984 Aug; 133(2):886-91. PubMed ID: 6376630
[TBL] [Abstract][Full Text] [Related]
30. The human complement C1 complex has a picomolar dissociation constant at room temperature.
Tseng Y; Zavodszky P; Schumaker VN
J Immunol; 1997 Jan; 158(2):937-44. PubMed ID: 8993014
[TBL] [Abstract][Full Text] [Related]
31. Expression of active human C1 inhibitor serpin domain in Escherichia coli.
Lamark T; Ingebrigtsen M; Bjørnstad C; Melkko T; Mollnes TE; Nielsen EW
Protein Expr Purif; 2001 Jul; 22(2):349-58. PubMed ID: 11437612
[TBL] [Abstract][Full Text] [Related]
32. C1 subcomponent complexes: basic and clinical aspects.
Laurell AB; Sjöholm AG
Behring Inst Mitt; 1993 Dec; (93):292-8. PubMed ID: 8172579
[TBL] [Abstract][Full Text] [Related]
33. Identification of a new P1 residue mutation (444Arg----Ser) in a dysfunctional C1 inhibitor protein contained in a type II hereditary angioedema plasma.
Aulak KS; Cicardi M; Harrison RA
FEBS Lett; 1990 Jun; 266(1-2):13-6. PubMed ID: 2365061
[TBL] [Abstract][Full Text] [Related]
34. Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats.
de Smet BJ; de Boer JP; Agterberg J; Rigter G; Bleeker WK; Hack CE
Blood; 1993 Jan; 81(1):56-61. PubMed ID: 8417802
[TBL] [Abstract][Full Text] [Related]
35. Reactivity of alpha 1-antitrypsin mutants against proteolytic enzymes of the kallikrein-kinin, complement, and fibrinolytic systems.
Patston PA; Roodi N; Schifferli JA; Bischoff R; Courtney M; Schapira M
J Biol Chem; 1990 Jun; 265(18):10786-91. PubMed ID: 2191958
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and regulation of C1 inhibitor in human skin fibroblasts.
Katz Y; Strunk RC
J Immunol; 1989 Mar; 142(6):2041-5. PubMed ID: 2537870
[TBL] [Abstract][Full Text] [Related]
37. The structure and function of the first component of complement: genetic engineering approach (a review).
Gál P; Cseh S; Schumaker VN; Závodszky P
Acta Microbiol Immunol Hung; 1994; 41(4):361-80. PubMed ID: 7866721
[TBL] [Abstract][Full Text] [Related]
38. Heparin-stimulated modification of C1-inhibitor by subcomponent C1s of human complement.
Weiss V; Engel J
Hoppe Seylers Z Physiol Chem; 1983 Mar; 364(3):295-301. PubMed ID: 6602754
[TBL] [Abstract][Full Text] [Related]
39. C1 activation and dissociation in disease.
Laurell AB; Mårtensson U; Sjöholm AG
Immunol Lett; 1987 Feb; 14(3):249-53. PubMed ID: 3032782
[TBL] [Abstract][Full Text] [Related]
40. Autoantibody facilitated cleavage of C1-inhibitor in autoimmune angioedema.
Jackson J; Sim RB; Whaley K; Feighery C
J Clin Invest; 1989 Feb; 83(2):698-707. PubMed ID: 2536404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
